Skip to main
BNTX
BNTX logo

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 27%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech's financial outlook is bolstered by its substantial cash position, ending the third quarter of 2025 with approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables, providing a strong foundation for continued investment in R&D and pipeline development. The positive developments surrounding BNT323, aimed at hormone receptor-positive, HER2-low metastatic breast cancer, enhance expectations for the ongoing global Phase 3 DYNASTY-Breast02 trial, which could lead to significant breakthroughs in the oncology domain. Furthermore, the emerging data on the LP.8.1-adapted monovalent COVID-19 vaccine indicates robust immune responses against multiple SARS-CoV-2 sublineages, showcasing the company's ability to adapt its vaccine portfolio in response to evolving public health needs.

Bears say

The financial outlook for BioNTech appears negative due to several fundamental risks, including negative data across multiple drug candidates in its oncology pipeline, which could adversely affect market confidence. Additionally, the company reported a net loss per diluted share of €0.12 for the third quarter of 2025, with projections indicating a full-year loss of €3.99 per share, highlighting ongoing financial challenges. Furthermore, the dynamics in the COVID-19 vaccine market pose significant headline risks that may shift investor focus away from BioNTech's oncology portfolio, complicating the company's growth trajectory.

BioNTech SE (BNTX) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 27% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 11 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Dec 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $137.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $137.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.